SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

Following the 2017 American College of Rheumatology (ACR) Annual Meeting—held in San Diego, California, November 3-8—Medscape spoke with Hospital for Special Surgery rheumatologists Dr Robert F.

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

The drug tofacitinib was well tolerated among patients with early scleroderma, primarily affecting the protein interferon both in fibroblasts and keratinocytes. Researchers say the drug is safe and ...

Q: My daughter, who is 14-years-old, was diagnosed with localized scleroderma about three years ago, and I am finding out that not much is known on this disease. Could you tell be about it? Does it ...